Parkinson’s UK is investing £2.1million to support Neumora Therapeutics to carry out preclinical testing of NMRA-NLRP3, a NLRP3 inhibitor with the potential to reduce inflammation and protect brain cells in Parkinson’s. NLRP3 is a protein that plays a role in regulating a number of inflammatory processes that are believed to contribute to the damage to brain cells that underlies Parkinson’s.
Intellia to respond to lawsuit over in vivo therapy patents
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS